2nd time lucky for Sanofi-GSK after passing small midstage COVID shot; eye approval by year-end HIMSS, HLTH conferences will require attendees, exhibitors to be fully vaccinated for COVID-19 Prepping the next generation of COVID-19 vaccines and treatments CMS: Mental health services decline by double-digits for Medicaid, CHIP beneficiaries last year ACC 2021: AstraZeneca's Farxiga failed to help COVID-19 patients, but it’s safe for them to use UPDATED Coronavirus tracker: Many vaccine-hesitant Americans fearful of inaccurate symptoms, poll shows COVID-19 tracker: U.S. to share at least 20 million doses; Moderna, Pfizer shots hold up against variants in new study ACC 2021: Cardiac ultrasound AI outperforms doctors at predicting COVID-19 death risks Pfizer, Moderna COVID-19 vaccines induce responses against 2 key variants, small study finds PerkinElmer opens COVID-flush wallet for $155M immunodiagnostics buy Featured Story | By Ben Adams After fumbling their first attempt, once rivals but now partners Sanofi and GlaxoSmithKline have passed a small phase 2 COVID-19 vaccine test, plotting a much larger phase 3 in the coming weeks and a 2021 approval. read more |
| |
|---|
|
Top Stories By Heather Landi The largest healthcare conference to put on an on-site event since the start of the COVID-19 pandemic will require attendees and exhibitors to show proof of full vaccination. read more By Arlene Weintraub Many biopharma companies are betting the novel coronavirus is here to stay—and they’re continuing to develop vaccines and drug treatments to keep it under control. They include CureVac, which said the next-gen version of its mRNA COVID vaccine was effective in a rodent study, and Memo Therapeutics, which described the antibody drug candidate it's developing. read more By Robert King New data released by CMS show how far mental health services declined among beneficiaries on Medicaid and CHIP from March through October 2020 due to the pandemic. read more By Noah Higgins-Dunn AstraZeneca’s Farxiga may not have hit its marks in a COVID-19 trial, but it did well enough to keep trying, the study’s lead author said. On top of that, its performance on the safety side may help dispel doctors' fears that SGLT2 drugs could cause serious side effects in COVID-19 patients. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner Sanofi and GSK reported their COVID-19 vaccine performed well in a phase 2 study, and now the pair plan on initiating a larger phase 3 trial with the aim of a late 2021 approval. UNICEF's chief called on G7 countries to make an emergency donation of doses to COVAX, which is facing supply shortages. And more headlines. read more By Conor Hale The AI was more accurate in predicting severe cases than a panel of experts trained in echocardiograms, while the study also showed that the use of AI led to less variability between scans and readers. read more By Kevin Dunleavy A study of T cell responses shows that mRNA vaccines produced by Moderna and Pfizer-BioNTech are as effective against the U.K. and South African variants of COVID-19 as they are against the original strain, among other findings. read more By Conor Hale PerkinElmer aims to spend some of the windfall its reaped over the past year from COVID-19 testing on a new acquisition, and similarly tapping yet another smaller European test maker to bolster its core business. read more |
